TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

This study is testing a combination treatment for liver cancer that has blocked blood flow in a major vein (portal vein tumor thrombosis). It combines a procedure to reroute blood flow through the liver with an immunotherapy drug called cadonilimab. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with liver cancer (hepatocellular carcinoma) with portal hypertension caused by tumor in the portal vein - Your cancer is advanced (BCLC stage C) but your liver function is still relatively preserved - You have not previously received targeted therapy or immunotherapy - You are in good general health (ECOG score 0–1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your liver is very severely damaged (Child-Pugh score above 13) - You have had certain serious heart, liver, or blood abnormalities - You have autoimmune diseases or are on immunosuppressive medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.